Immutep
Immutep Ltd (formerly Prima Biomed) is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Basic Information
- Category: pharmaceutical industry
- Founded: 2001
- Headquarters: Sydney
- Website: http://www.immutep.com/
Documented Facts
- Phone: +61283157003 (No linked source recorded for this statement.)
- Email: enquiries@immutep.com (No linked source recorded for this statement.)
- Founded: 2001 (No linked source recorded for this statement.)
- Website: http://www.immutep.com/ (No linked source recorded for this statement.)
- Headquarters: Sydney (No linked source recorded for this statement.)
- Industry: pharmaceutical industry (No linked source recorded for this statement.)
- Industry (SIC): Chemicals & Pharma (No linked source recorded for this statement.)
- State of Incorporation: C3 (No linked source recorded for this statement.)
- Stock ticker: PRRUF (OTC) (No linked source recorded for this statement.)
Evidence and Sources
- Immutep — Official Site (official)
- Immutep on facebook (social)
- Immutep on linkedin (social)
- Immutep — Wikipedia (reference)
- IMMUTEP Ltd — SEC EDGAR (reference)
Citation Guidance
Explore pharmaceutical industry profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Immutep.
- Canonical profile: https://brandsource.ai/brands/immutep
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/immutep/json-ld
- Citation profile API: https://brandsource.ai/api/brands/immutep/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (94/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-21
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Immutep Ltd (formerly Prima Biomed) is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 4 supporting sources linked.
- 9 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.